60 Degrees Pharmaceuticals Will Release Clinical Data
The company will share interim results for its babesiosis treatment study on October 6, 2026.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize finding treatments for rare diseases?
60 Degrees Pharmaceuticals is scheduled to release interim clinical trial data for its babesiosis treatment on October 6, 2026. The company will also host an investor webinar at 11:00 a.m. ET to discuss the findings from clinical study NCT06207370.
Why it matters
There is currently no FDA-approved treatment or vaccine for babesiosis, a vector-borne disease. 60 Degrees Pharmaceuticals aims to address this critical unmet medical need for patients suffering from treatment-refractory cases.
The clinical study evaluates the efficacy of tafenoquine, a drug currently approved as ARAKODA for malaria prophylaxis, in patients with severe babesiosis. This research marks a move to repurpose existing therapies for tick-borne diseases.
The players
60 Degrees Pharmaceuticals
A Washington, D.C.-based biotech company founded in 2010 that specializes in developing medicines for vector-borne diseases.
Peter Krause
A medical expert and Key Opinion Leader who will present findings at the upcoming investor webinar.
Edouard Vannier
A medical expert who will provide insights during the clinical study discussion at the company's investor event.
The details
The upcoming webinar will feature presentations from Dr. Peter Krause and Dr. Edouard Vannier regarding the potential of tafenoquine to treat recurrent infections. The company, headquartered in Washington, D.C., has focused on developing medicines for vector-borne diseases since its founding in 2010.
Timeline
2010: 60 Degrees Pharmaceuticals was founded.
2018: ARAKODA received FDA approval for malaria prevention.
March 30, 2026: Company filed Annual Report on Form 10-K with SEC.
October 6, 2026: Interim data release and investor webinar at 11:00 a.m. ET.
The Tech Race
The potential use of ARAKODA for babesiosis follows a pattern set by previous drug repurposing efforts in the biotech industry. By leveraging existing clinical approvals, developers aim to accelerate timelines in the high-stakes race to fill gaps in infectious disease treatment.
Patients suffering from treatment-refractory babesiosis may gain access to a new therapeutic option if the trial data proves successful. The outcome of this study remains highly significant given the total lack of current FDA-approved standard-of-care treatments for the disease.
The takeaway
The study highlights the industry trend of repurposing existing FDA-approved malaria drugs to address emerging tick-borne threats. Investors and patients should monitor the upcoming data release for updates on the company's long-term financial and operational viability.
What happens next
The company will hold an investor webinar on October 6, 2026, at 11:00 a.m. ET.
Further reading
For more information on ongoing clinical developments, visit the Biotech section.
Live Poll
Do you trust pharmaceutical companies to prioritize finding treatments for rare diseases?
